to recent Officer; third and our Henry review financial Development results Henry. along highlights. today's our business Officer. XXXX Chief our Financial Jim our Chief for you, Thank thanks morning to quarter discuss And joining Rob Commercial Weiskopf, with everyone Officer; call, Blakey, Carr, me Also are and on Brian Clinical this joining Chief us
about Summit it's this discussing off Xb is Phase recently dry this discussions program. enrolled. at our AMD clinical by dry We're for dry about And indications dysfunction talking in were trial AMD on the patients a those this AMD XX% kick mitochondrial month. there like growing importance We ophthalmic clear our role in that geographic of disease. the enrollment completing the of from we'll recognition of we're atrophy, bioenergetics in earlier mitochondrial cusp with of So,
make and also night ongoing completing additional implemented help and accessible during including enrollment We've the year-end. target our weekend some our more to of We opened visits nurses. sites sites have patient-centric visiting protocol to pandemic, by meet
our assess early our monitoring upsize any impact of necessary, enrollment to criteria, which enrollment related the sites incident into to QX. continually extend country could we our are discontinuation. as will If target meet across COVID-XX as the rates well We
current plans no have we that. to However, do
to signed mortality work clinicians Barth adolescents strong unmet activities of the community FDA of relationships mitochondrial geographic to own to looks Our patients To Stealth in daily which diseases a Unlike ultra-rare Americans, over lead example, dysfunction. rare even people affects life early manifest diseases to therapies diseases, is a have not appetite sometimes is other they over with diseases is patient the at eligible like, we've with understood mission X,XXX most members children really provide and need Barth in Syndrome group These cases, adults, known altering petition how young and us the for living. of negatively XXX impacts atrophy, provide syndrome, as the case in these to well better they to result possible. Americans. what with often are which asking soon groups. In illness, million severe as and cases, some syndrome. of conduct core understand advocacy involving suffering terms to are from diseases. than characterized. their always or burden diseases which less affect they well in these lives a patient's Recently, developed a Barth to ability to of Barth In a access
seriously. of drug they read. the syndrome Barth application our existing dying, a are petition feedback with and very ask we treatment a have need We now. this choices kind submit that new life, of clinical from Individuals We Specifically, quality trials. based evidence patient many take on reduced
by the our commitment year Barth community our efforts and progress reaffirmed to end. NDA including pledged regulatory planned a to have with agency, submission We the
an of medical NDA our prior sufficient that our however, data was the QX genetics rare did update, support division package during agree disease As not to and we submission. shared
the improve approval overall flexibility So, be we to light can by in have standards for which afforded believe and of data additional we diseases. rare setting FDA we meet believe accepted various for which should package, documents the conducted in of the review, some analysis guidance
we our taking However, NDA risk agency's recognized a be additional accepted are control we to address or there to approved, not that steps that recommendation collect will is also the data. since
This suggested pre-specified time consider our placebo to to period, DRDMG extension, example, event that in approved. example elamipretide additional generate control accepted approach could randomizing For be half to as the the near-term like. a what that would would or a the NDA randomized of one for on of of look data withdrawal remaining not them is and entail which other open-label we patients half
step natural structure material given -- function can post-marketing addition, controlled Phase long-term still observed, X commitment. an robust we as decline have differ and study, In history the next scientifically we the expected of of adverse assessing in our We that placebo the elamipretide improvements that likelihood think a reduce cardiac Barth. be events, outcome which whether would the from in cardiac
was outcomes walk. in functional in in observed as like our we additional request we increases placebo currently Genetics X with treatment so a controlled elamipretide extension. our as improvements not that trials, which SPIBA-XXX, long-term While pre-NDA was label the at coinciding of benefit change study them elamipretide protocols, ventricular SPIBA-XXX, X in weeks. with presented our was demonstrating crossover Society over index Medicine efficacy study slope in therapy plan submit to was to averaged which natural history the to Phase Data that IND and retrospective Barth long-term of these American data upcoming open the the recently DRDMG left compared Barth, well do We've October, of discuss controls, evaluate from Phase and of to meeting our volume, observed to a six-minute stroke with to plan subjects domain do with presented
at symposium. over this Barth function what other improve, mentioned suggest summer the to tolerance heart Foundations previously is So, endpoints the may sense XXXX also which exercise as We've functional and improve, that Syndrome makes us. presentations
Other portion So, indicators to than placebo we detail publication do expect won't those note were we SPIBA-XXX the that during Medicine, medical of and now to placebo upcoming that a controlled to note observed that data inefficient which in journal. also improvements in the has detail Genetics metabolism, is in mitochondrial an of more bring in been peer-reviewed to from you address and published again. clinical through relative metabolomic SPIBA-XXX,
other shared plans We development expand into to you also previously with efforts diseases. our our elamipretide rare
questions brief like details So where give people is just and to a efforts those more of going you take of there can interest we would to that stand, hear. if summary
quarter be assess this open-label, an This effect year. with the elamipretide next will it patients trial progressively So, clinical investigator-initiated X our Friedreich's help trial is Friedreich's. current will to design. in the well-characterized function, Phase support decline cardiac starting natural visual on of plan and first both subsequent ataxia of hope which that history We pivotal trial inform us will of in of
to We associated in protocol for design with are trial Duchenne evaluate continuing with dystrophy. muscular also patients a cardiomyopathy
is key to goal leaders, Our advocacy second indication as opinion as initiate the of a for patient And this in our during have well half XXXX. initiative. this support trial expressed
in myopathy changes during their were mutations mentioned in with treated Phase Most in test previously patients nuclear that placebo in genetic improved have of also there subgroup that primary also of no six-minute gamma the trial, mutations. replication. the walk were in with nuclear mitochondrial walks X the distance the called patients that patients which gene, subgroup, these and DNA the mitochondrial similarly in related mutations DNA disorders. lead included. that mitochondrial proteins in genes proteins other replisome mutations disorders had the They preliminaries replication, these for encode required encodes involved all Mutations for from subgroup, nuclear DNA We to
blood-brain compound relative in and a stage to continuing neurology higher compound demonstrated would expect remains our Phase concentration is of patients, next improve advanced protocol of pipeline most a evaluate are a in that profile SBT-XXX, the commence a to administered With respect year. in pleased for CNS human a volunteers. to subgroup key also focus. is share pipeline which X safety penetration our trial the healthy that demonstrated we So which design We're SBT-XXX has elamipretide. of to we clinical The favorable orally barrier to the
Alzheimer's. We a neurons. indication evidence in and where TDP patients. role Lewy TDP-XX multiple we've and neuronal pathology drug new model selection, It's X model two to XXXX motor Supranuclear of plans, October, of neurological Lobar a NEALS neurite TDP been survival Frontotemporal ALS, improved in Meeting a in presented Annual dosing. may plays saw where to studies cell initiated Palsy in will Body subcutaneous at diseases we be ALS, inform upper are observed Progressive neurological Phase primary we including observed Degeneration, in exposure tox protection death. Dementia, neuronal in branching next respect models. the disease and the improved length we With trial different enable Long-term to SODX now assessing saw formulation explore year That's
data with Parkinson's, share a and associated to an upcoming Lewy and atrophy. dementia [indiscernible] at multiple system is body conference. expect disease model pathology We This
So X XXX Phase it's development. also for therapeutic three so confidence indication. SBT-XXX in about reinforced We're will inform neurological our and data together, indications, series these disease in candidate, clinical a help as all our obviously us excited our that neurological earlier
we've potential. continue with We the year. challenging for what's We're been our great pleased made platform enthusiasm really progress a have to during
Our to we apply important for progress in, learned determined to lessons leaning targeted team therapies is have mitochondrial energized and the patients.
financial development funding continued sites execute to we're agreements that on position mission goals. recently thrilled a financial [indiscernible] that and our with in are stronger We under announced our support
So, our quarter the updates with to Rob over that and to to recent review results. I'm financial turn call third going
